The pan-tumor KRAS G12C subset was notably distinct from cases with non-G12C mutations or KRAS WT, with patients carrying G12C mutant tumors being older (median age 66 vs 64 vs 64 years), more often female (58% vs 52% vs 54%), having higher TMB (32% vs 12% vs 16% with TMB ≥ 10 mutations/Mb), and a greater fraction with high PD-L1 expression (37% vs 14% vs 14%) (all comparisons p < 0.001). The gene discussed is KRAS; the disease is neoplasm.